Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) EBT (2016 - 2025)

Mimedx's EBT history spans 15 years, with the latest figure at $21.8 million for Q4 2025.

  • For Q4 2025, EBT rose 93.74% year-over-year to $21.8 million; the TTM value through Dec 2025 reached $66.3 million, up 15.65%, while the annual FY2025 figure was $66.3 million, 15.65% up from the prior year.
  • EBT for Q4 2025 was $21.8 million at Mimedx, down from $22.8 million in the prior quarter.
  • Across five years, EBT topped out at $23.2 million in Q2 2024 and bottomed at -$10.8 million in Q2 2022.
  • The 5-year median for EBT is $9.0 million (2023), against an average of $5.7 million.
  • The largest YoY upside for EBT was 10732.97% in 2022 against a maximum downside of 505.72% in 2022.
  • A 5-year view of EBT shows it stood at $91000.0 in 2021, then surged by 10732.97% to $9.9 million in 2022, then surged by 41.13% to $13.9 million in 2023, then dropped by 19.15% to $11.2 million in 2024, then surged by 93.74% to $21.8 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's EBT are $21.8 million (Q4 2025), $22.8 million (Q3 2025), and $13.0 million (Q2 2025).